Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å sjekke leverhelsen hos gutter med XLMTM, en alvorlig genetisk muskeltilstand (EXCEL)

29. september 2026 oppdatert av: Astellas Gene Therapies

En ikke-intervensjonell, epidemiologisk studie av XLMTM og klinisk uttrykk i leveren

XLMTM (X-linked myotubular myopathy) is a serious genetic muscle condition. It is caused by changes in the MTM1 gene which stops or slows down normal muscle development, causing severe muscle weakness. There is currently no cure for XLMTM. Ongoing care is needed to manage symptoms and prevent further medical problems from this condition.

Recent research shows that individuals with XLMTM often have reduced bile flow which can affect liver and gallbladder health. Bile is a liquid made in the liver that helps digest fat. Ongoing liver health checks may help with the routine care of people with XLMTM.

There is a need to understand liver problems that develop in individuals with XLMTM over time. The main aim of the study is to learn how many boys with XLMTM have new cases of liver problems during the study.

This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the study sponsor (Astellas).

In this study, boys under 18 diagnosed with XLMTM will be followed for about 1 year. The health of their liver and gallbladder will be checked about every 6 weeks. This can be done at home, if preferred. A scan called a Fibroscan (also known as transient elastography) will check for signs of scarring in the liver (fibrosis) and the build-up of lipids. It is suggested that each boy will have a Fibroscan when they start the study and another scan when they complete the study.

This study will help understand liver, gallbladder, and bile duct issues in individuals with XLMTM over time. The goal is to improve their care and provide information to use in future clinical studies.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Studietype

Observasjonsmessig

Registrering (Antatt)

50

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Ontario
      • Toronto, Ontario, Canada
        • Rekruttering
        • Site CA15001
    • California
      • Santa Monica, California, Forente stater, 90401-2072
        • Rekruttering
        • UCLA Neurological Services
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
        • Rekruttering
        • Ann & Robert H. Lurie Children's Hospital of Chicago
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02115
        • Rekruttering
        • Boston Children's Hospital
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45229
        • Rekruttering
        • Cincinnati Children's Hospital Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Rekruttering
        • Children's Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, Forente stater, 15224
        • Rekruttering
        • UPMC Children's Hospital of Pittsburgh
    • Utah
      • Salt Lake City, Utah, Forente stater, 84112
        • Rekruttering
        • University of Utah
      • Leeds, Storbritannia
        • Rekruttering
        • Site GB44006
      • London, Storbritannia
        • Rekruttering
        • Site GB44003
      • Oxford, Storbritannia
        • Rekruttering
        • Site GB44005

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

Ikke eldre enn 17 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Mann

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Approximately 50 male participants < 18 years of age with genetically confirmed XLMTM will be enrolled at specialist sites.

Beskrivelse

Inclusion Criteria:

  • Participant has a diagnosis of XLMTM resulting from a genetically confirmed mutation in the MTM1 gene based on genetic test reports.
  • Participant requires some mechanical ventilatory support (e.g., ranging from 24 hours per day full-time mechanical ventilation, to non-invasive support such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) during sleeping hours)
  • Participant (as applicable) and/or parent(s)/carer is willing to comply with the recommended schedule of assessments.

Exclusion Criteria:

  • Participant is currently enrolled in an interventional study designed to treat XLMTM.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Participants with XLMTM

Pediatric and adolescent participants with XLMTM.

No investigational drug will be administered to participants in this study.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence rate of cholestasis
Tidsramme: Up to Week 48

Calculated as the number of new cases of cholestasis over 48 weeks divided by total duration of follow-up for enrolled participants.

Up to Week 48
Point prevalence of cholestasis
Tidsramme: Day 1

Point prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis prior to Day 1 (baseline).

Day 1
Prevalence of cholestasis
Tidsramme: Up to 1 year

Prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis within 1 year of Day 1 (baseline).

Up to 1 year

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Genetic variants of MTM1
Tidsramme: Up to Week 48

The association between genetic variants of MTM1 and cholestasis will be evaluated.

Up to Week 48
Risk of cholestasis temporarily associated with environmental modifiers
Tidsramme: Up to Week 48

Medication use, immunization history, infectious disease history and dietary habits will be collected.

Up to Week 48
Hospitalizations
Tidsramme: Up to Week 48

Frequency and reason for hospitalizations will be collected.

Up to Week 48
Duration of Hospitalizations
Tidsramme: Up to Week 48

Duration of hospitalization visits will be collected.

Up to Week 48
Emergency room visits
Tidsramme: Up to Week 48

Frequency and reason for visit will be collected.

Up to Week 48
Hepatology specialist visits
Tidsramme: Up to Week 48

Frequency and reason for visit will be collected.

Up to Week 48
Scheduled/unscheduled office visits
Tidsramme: Up to Week 48

Frequency and reason for visit will be collected.

Up to Week 48
Non-study-specified home healthcare visits
Tidsramme: Up to Week 48

Frequency and reason for visit will be collected.

Up to Week 48
Surgeries/procedures
Tidsramme: Up to Week 48

Frequency and type will be collected.

Up to Week 48

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studieleder: Medical Director, Astellas Gene Therapies

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

19. mai 2025

Primær fullføring (Antatt)

31. desember 2027

Studiet fullført (Antatt)

31. desember 2027

Datoer for studieregistrering

Først innsendt

19. august 2024

Først innsendt som oppfylte QC-kriteriene

29. august 2024

Først lagt ut (Faktiske)

3. september 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

30. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere